'Authorized Biosimilars' Can't Use 351(k) Pathway, US FDA Concludes

 
• By Sue Sutter
  
Calendar_23_March
US FDA is finalizing preparations for the regulatory transition that will take place on 23 March. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics